Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 9/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.31 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.31 |
| ▸ | ATF1 | P18846 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18113889 | 0.88 | ABL1 (0.37) | POLQP2RY1ABL1PIK3CGATF1 | |
| SCHEMBL18113948 | 0.88 | POLQ (0.36) | POLQP2RY1PIK3CGATF1NFKB1 | |
| SCHEMBL18113859 | 0.88 | ABL1 (0.41) | POLQABL1PIK3CGMALT1 | |
| SCHEMBL18113820 | 0.86 | P2RY1 (0.47) | POLQP2RY1DUSP3 | |
| SCHEMBL20481615 | 0.86 | POLQ (0.39) | POLQP2RY1ABL1PIK3CGATF1 | |
| SCHEMBL18113802 | 0.84 | PI4KB (0.35) | POLQP2RY1ABL1PIK3CGPI4KB | |
| SCHEMBL18113817 | 0.83 | ABL1 (0.40) | POLQP2RY1ABL1PIK3CGPI4KB | |
| SCHEMBL18113771 | 0.83 | HDAC4 (0.36) | POLQP2RY1PI4KBMALT1 | |
| SCHEMBL18113902 | 0.83 | P2RY1 (0.39) | P2RY1ABL1DUSP3ADORA3 | |
| SCHEMBL18113960 | 0.83 | MALT1 (0.36) | POLQP2RY1ABL1MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180243298-A1 | TRPV3 MODULATORS | ABBVIE INC. | 2018-08-30 | — | — | US | claimed |
| WO-2016160938-A1 | N-(1,3-THIAZOL-2-YL)PYRIMIDINE-5-CARBOXAMIDES AS TRPV3 MODULATORS | ABBVIE INC. (US) | 2016-10-06 | — | — | WO | claimed |
| US-20180243298-A1 | TRPV3 MODULATORS | ABBVIE INC. | 2018-08-30 | — | — | US | disclosed |
| WO-2016160938-A1 | N-(1,3-THIAZOL-2-YL)PYRIMIDINE-5-CARBOXAMIDES AS TRPV3 MODULATORS | ABBVIE INC. (US) | 2016-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180243298-A1 | TRPV3 MODULATORS | TRPV3, TRPV1, TRPV2 | POLQ 4676/4885P2RY1 155/4885ABL1 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.